Version history

{
  "description": "Extracellular vesicles (EVs), including exosomes and microvesicles, carry molecular cargo (proteins, miRNAs, lipids) from their cells of origin, including neurons, astrocytes, and microglia. Brain-derived EVs can cross the blood-brain barrier and be isolated from blood, CSF, or saliva, potentially serving as liquid biopsy biomarkers for Alzheimer disease. Key questions: Which EV-derived biomarkers (e.g., phospho-tau, amyloid-beta, synaptic proteins, inflammatory mediators) show the highest diagnostic accuracy for early/prodromal AD? How do EV subpopulations (neuronal vs glial origin) differ in their biomarker profiles? What are the technical challenges in EV isolation and characterization that limit clinical translation?",
  "domain": "neurodegeneration",
  "status": "partially_addressed",
  "priority_score": 0.92,
  "importance_score": 0.9,
  "tractability_score": 0.85,
  "novelty_score": 0.8,
  "composite_score": 0.85,
  "source": "orchestra-slot-4",
  "evidence_summary": "{\"hypothesis_matches\": [{\"id\": \"h-29ef94d5\", \"title\": \"Epigenetic Memory Reprogramming for Alzheimer's Disease\", \"target_gene\": \"BDNF, CREB1, synaptic plasticity genes\", \"target_pathway\": \"CREB/BDNF epigenetic regulation of synaptic plasticity\", \"match_score\": 0.44, \"composite_score\": 0.49103059326293774, \"status\": \"proposed\"}, {\"id\": \"h-d78123d1\", \"title\": \"Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery\", \"target_gene\": \"RAB27A/LAMP2B\", \"target_pathway\": \"Extracellular vesicle biogenesis (ESCRT/Rab27a) / mitochondrial transfer\", \"match_score\": 0.4, \"composite_score\": 0.3681729702065991, \"status\": \"proposed\"}, {\"id\": \"h-8b7727c1\", \"title\": \"Targeting Bacterial Curli Fibrils to Prevent \\u03b1-Synuclein Cross-Seeding\", \"target_gene\": \"CSGA\", \"target_pathway\": \"Bacterial curli amyloid \\u2192 \\u03b1-synuclein cross-seeding (gut-brain axis)\", \"match_score\": 0.37, \"composite_score\": 0.4361439227893742, \"status\": \"proposed\"}, {\"id\": \"h-aa2d317c\", \"title\": \"Magnetosonic-Triggered Transferrin Receptor Clustering\", \"target_gene\": \"TFR1\", \"target_pathway\": \"Blood-brain barrier transport\", \"match_score\": 0.3, \"composite_score\": 0.4206402486635706, \"status\": \"proposed\"}, {\"id\": \"h-73e4340b\", \"title\": \"Pericyte Contractility Reset via Selective PDGFR-\\u03b2 Agonism\", \"target_gene\": \"PDGFRB\", \"target_pathway\": \"Blood-brain barrier transport\", \"match_score\": 0.3, \"composite_score\": 0.41877335787359243, \"status\": \"proposed\"}, {\"id\": \"h-9d22b570\", \"title\": \"Programmable Neuronal Circuit Repair via Epigenetic CRISPR\", \"target_gene\": \"NURR1, PITX3, neuronal identity transcription factors\", \"target_pathway\": \"CRISPRa epigenetic activation of dopaminergic transcription factor network\", \"match_score\": 0.27, \"composite_score\": 0.4470493886505538, \"status\": \"proposed\"}, {\"id\": \"h-1e28311b\", \"title\": \"Microglial ACE Enhancement for Amyloid Clearance\", \"target_gene\": \"ACE\", \"target_pathway\": null, \"match_score\": 0.27, \"composite_score\": 0.38216700564668704, \"status\": \"proposed\"}, {\"id\": \"h-7693c291\", \"title\": \"RNA-Binding Competition Therapy for TDP-43 Cross-Seeding\", \"target_gene\": \"TARDBP\", \"target_pathway\": \"TDP-43 RNA-binding / liquid-liquid phase separation cross-seeding\", \"match_score\": 0.27, \"composite_score\": 0.3721712615349977, \"status\": \"proposed\"}, {\"id\": \"h-a4e259e0\", \"title\": \"Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication\", \"target_gene\": \"CHRNA7\", \"target_pathway\": \"Vagal cholinergic anti-inflammatory pathway (\\u03b17nAChR)\", \"match_score\": 0.24, \"composite_score\": 0.4601336707597654, \"status\": \"proposed\"}, {\"id\": \"h-trem2-6a46fa2c\", \"title\": \"Stage-Specific TREM2 Biomarker-Guided Switching \\u2014 Agonist in Amyloid Phase, Antagonist in Tau Phase\", \"target_gene\": \"TREM2, APOE, MAPT\", \"target_pathway\": \"disease staging, precision medicine\", \"match_score\": 0.24, \"composite_score\": 0.4527421608193062, \"status\": \"proposed\"}], \"total_matching_hypotheses\": 22, \"gap_tokens_sample\": [\"AD\", \"CSF\", \"EV\", \"EV-derived\", \"EVs\", \"accuracy\", \"alzheimer\", \"amyloid\", \"amyloid-beta\", \"astrocytes\", \"barrier\", \"biomarker\", \"biomarkers\", \"biopsy\", \"blood\"], \"updated_at\": \"2026-04-06T08:21:05.841636+00:00\"}",
  "resolution_criteria": "Resolved when: a curated dataset or review ranks brain-derived EV biomarkers for early AD by diagnostic performance, sample type, assay, cohort size, and replication status, with at least two independent studies per top marker or a clear single-study limitation. SciDEX must add KG edges connecting EV cargo, source cell type, biofluid, assay, disease stage, and clinical use, plus a debate or scored hypothesis on readiness.",
  "market_price": 0.5
}